Geron Initiates Phase 2 of GRN1005 in Brain Metastases From Breast Cancer

Geron Initiates Phase 2 Trial of GRN1005 in Brain Metastases From Breast Cancer
Great news! If Geron can get good results, it will be fast tracked. In patients with brain metastases from solid tumors, overall response rate was 20% (4/20) by one dimensional assessment when treated with a dose of 650 mg/m(2) of GRN1005 administered as single-agent therapy once every three weeks.

Good luck in this rigged casino,

No news for Geron

Geron volume was only 814,240 shares over five days. Ten day avg. volume was 1,042,103 and three months was 1,517,420 shares. The high for the week was $1.77 on Monday the low $1.55 on Thursday.
Need  partners.
Celgene, Pfizer and Teva Pharm. are in stem cell research, small time. Partnering with Geron would make them big time and they have the money to fund the research.

The share price is worrying me. It could go below a dollar. Waiting for a parnter.  Good news from the four Phase II trials will raise the share price. If by the end of 2012 the results from the 4 Phase II trials are anything but outstanding, I will sell most of my shares. For now any move over $2, I will sell some shares and sell a few covered calls.

I put a lot of time and money into Geron, believing [and still do] in the stem cell program, now there is very little reason for me to hold a large position in this company. Will cut my position by at least half.

Good luck in this rigged casino,

No news is the story for Geron

No news on the patent case against Viacyte. No news on anyone buying Geron's stem cell program. No news on partnering. No increase in volume or share price.
Just wait and see if "Chip" the new CEO can work some magic.

Good luck in this rigged casino,

Geron slowly moving up, why

The patent case against Viacyte is coming to a end. We should have an announcement Thursday or early next week. Hoping it's good news for longs. Geron share price is $1.76 up 9 cent. at 1:36PM.

Good luck in this riggeed casino,

GRN1005 recruiting patients

That's great news, on schedule.
 From Geron Website-
Our clinical development plan for GRN1005 includes a Phase 2 clinical trial in patients with brain metastases arising from NSCLC and breast cancer. If the data from the previously completed Phase 1 trial in metastatic brain cancer are confirmed, and depending upon the strength of the data, the product candidate may have an opportunity for early marketing approval.
We have also entered into a research and collaboration agreement with Angiochem to utilize these receptor-targeting peptides to transport telomerase inhibitors into the CNS.

Good luck in this rigged casino,

Insider buying a good sign

 

  There’s an old saying on Wall Street about insider buying: there are many possible reasons to sell a stock, but only one reason to buy. Back on November 22, Geron Corp.’s Director, Thomas Kiley, invested $100,269.00 into 64,275 shares of GERN, for a cost per share of $1.56. Bargain hunters tend to pay particular attention to insider buys like this one, because presumably the only reason an insider would take their hard-earned cash and use it to buy stock of their company in the open market, is that they expect to make money.

Good luck in this rigged casino,

 

 

Geron needs a partner

The high and low for the week was on the same day Nov. 21st, Monday, $1.80 and $1.41. The $1.41 was a new 52 week low.  Volume was over 3 million for Monday but went back down to normal the next few days.

TJ descided to become active, to raise awareness and funding for spinal cord injury research in America.
Check out Tory's Head in the Clouds blog.

Let me bounce this idea off you folks. Ask Geron how much money in the bank it would take start and finish the Phase I trial. Then have people like TJ, Roman Reed and few famous people, raise the money, put it in a trust account. When the goal is reach the trial can begin. You could have a teletheon and  raise the money quickly.

I'm going to email Geron and see what they say about my idea.

Good luck in this rigged casino,